Alkermes Soars on Positive ADHD Drug Trial Results: What Investors Should Know
Alkermes stock rises following promising ADHD drug trial results. Explore the implications for the company and the market.
Insmed's FDA Priority Review: A Game Changer for INSM Investors
Insmed's stock reacts positively to FDA's Priority Review, signaling potential shifts for investors.
Trade with the conviction of the 1%.
Institutional-grade market intelligence delivered before the opening bell.
Wall Street Futures Up Amid AI Rally: What It Means for Canadian Investors
US stock futures soar on AI momentum while oil prices dip, presenting mixed signals for Canadian investors.
Xenon Pharmaceuticals' Strategic Shift: FDA NDA for Azetukalner Amid Psychiatry Pause
Xenon Pharmaceuticals submits an NDA for azetukalner while pausing psychiatry enrollment, hinting at a pivotal strategy …
Ultragenyx's Fayuvi Approval: A Milestone for Rare Disease Market Dynamics
Ultragenyx's stock surged 12.6% following FDA approval for Fayuvi, a therapy for Sanfilippo syndrome, signaling investor…
Nuvation Bio's FDA Label Update: A Game Changer for IBTROZI in ROS1+ Cancer Treatment
Nuvation Bio's recent FDA label update for IBTROZI signals a pivotal moment for investors, highlighting long-term effica…
MISTRAS Group's Acquisition by H.I.G. Capital: Market Impact and Investor Considerations
H.I.G. Capital's acquisition of MISTRAS Group raises questions about market valuations and investment opportunities.
Eli Lilly's Expanded Approval for Inluriyo-Combined Verzenio: What It Means for LLY Investors
Eli Lilly's recent FDA approval for Inluriyo in combination with Verzenio marks a significant milestone yet results in a…
Ultragenyx Pharmaceutical's Landmark FDA Approval: Implications for RARE Investors
Ultragenyx's FDA approval of Fayuvi for Sanfilippo syndrome Type A signals a significant market shift for RARE investors…
MISTRAS Group to Go Private: What It Means for Investors
MISTRAS Group is set to be acquired by H.I.G. Capital for $20.35 per share, marking a significant shift for investors.
Merck and Moderna's mRNA Cancer Vaccine: A Major Milestone for Oncology
Merck and Moderna's Phase 3 trial success for an mRNA cancer vaccine marks a pivotal moment in oncology.